CRNX – crinetics pharmaceuticals, inc. (US:NASDAQ)

News

Crinetics Pharmaceuticals Says First Patient Dosed in Phase 3 Trial of Atumelnant for Classic CAH [Yahoo! Finance]
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler [Yahoo! Finance]
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com